Daebongls.Co.,Ltd.

A078140

KR7078140001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 08/12/2025			5-day change	1st Jan Change
12,410.00 ^KRW	+0.08%		-1.12%	-7.66%

14/11	Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
06/11	Daebongls.Co.,Ltd. announces Annual dividend, payable on April 24, 2026	CI

Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2020.

Published on 10/05/2020 at 12:06 pm IST

S&P Capital IQ

Daebongls.Co.,Ltd.

+0.08%

From April 3, 2020 to June 30, 2020, the company has repurchased 21,241 shares, representing 0.19% for KRW 140.27 million. With this, the company has completed the repurchase of 21,241 shares, representing 0.19% for KRW 140.27 million under the buyback announced on April 3, 2020.

Latest news about Daebongls.Co.,Ltd.

14/11	Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
06/11	Daebongls.Co.,Ltd. announces Annual dividend, payable on April 24, 2026	CI
14/08	Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
15/05	Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
21/03	Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
14/11	Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
06/24/06	Daebongls.Co.,Ltd. announced that it has received KRW 30 billion in funding from Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Lindeman Asia Investment Corporation ands another investor	CI
04/24/04	Daebongls.Co.,Ltd. announced that it expects to receive KRW 30 billion in funding from Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Lindeman Asia Investment Corporation and another investor	CI
14/24/14	Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
16/24/16	Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
20/24/20	Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
21/23/21	Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
04/21/04	Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on February 26, 2021.	CI
04/21/04	Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on February 26, 2021.	CI
01/21/01	Daebongls.Co.,Ltd.’s Equity Buyback announced on February 26, 2021, has expired with 61,995 shares, representing 0.56% for KRW 616.17 million.	CI
26/21/26	Daebongls.Co.,Ltd. announces an Equity Buyback for 100,000 shares, for KRW 986 million.	CI
26/21/26	Daebongls.Co.,Ltd. authorizes a Buyback Plan.	CI
05/20/05	Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2020.	CI
05/20/05	Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2020.	CI
05/20/05	Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2020.	CI
05/20/05	Daebongls.Co.,Ltd.’s Equity Buyback announced on April 3, 2020, has expired with 76,415 shares, representing 0.69% for KRW 727.29 million.	CI
04/20/04	P&K Skin Research Center Co., Ltd. has completed an IPO in the amount of KRW 40.8639 billion.	CI
28/20/28	P&K Skin Research Center Co., Ltd. has filed an IPO.	CI
03/20/03	Daebongls.Co.,Ltd. announces an Equity Buyback for KRW 1,000 million worth of its shares.	CI
03/20/03	Daebongls.Co.,Ltd. authorizes a Buyback Plan.	CI

Chart Daebongls.Co.,Ltd.

Duration

Period

A078140: Dynamic Chart

Company Profile

Daebongls. Co., Ltd. is a Korea-based company engaged in the manufacture of raw materials for pharmaceuticals and cosmetics. The Company operates its business through two main divisions: cosmetic division, which provides aloe vera gels, beta carotens, calamines, diaformers, emulgades and others for conditioners, emulsifiers, emollients, polymers, thickeners and others; pharmaceutical division, which provides almagates, bentonites, calcitriols, erdosteines, fish oil and others for antibiotics, cough products, expectorants and others. In addition, it is involved in the provision of food chemical additives, fish feedstuff and others. The Company distributes its products within domestic market and to overseas markets, including Japan, America and other Southeast Asian countries.

Employees

131

Sector

Pharmaceuticals

Calendar

25/03 - Q4 2025 Earnings Release (Projected)

More about the company